Jonathan Gardner's profile photo

Jonathan Gardner

Charlottesville

Senior Reporter at BioPharma Dive

Senior reporter, BioPharma Dive. Father of 1, husband of 1, son of 2, brother of 2, uncle of 7. Opinions are mine. RTs are not endorsements. Darn good runner.

Featured in: Favicon biopharmadive.com Favicon healthcaredive.com Favicon newsbreak.com Favicon supplychaindive.com Favicon k12dive.com Favicon evaluate.com Favicon medtechdive.com Favicon cfodive.com Favicon greenbeltnewsreview.com Favicon legaldive.com

Articles

  • Novo abruptly ends obesity drug deal with Hims

    5 days ago | biopharmadive.com | Jonathan Gardner

    Dive Brief:Novo Nordisk is terminating a marketing deal for its obesity drug Wegovy with Hims & Hers Health just eight weeks after it began, claiming the telehealth company “has failed to adhere to the law which prohibits mass sales of compounded drugs.”Hims had marketed compounded Wegovy under laws that permit it to while a drug is in shortage, but the U.S. government said the shortage ended in February.

  • FDA to speed reviews for drugs supporting ‘national interests’

    1 week ago | pharmavoice.com | Jonathan Gardner

    This audio is auto-generated. Please let us know if you have feedback. Food and Drug Administration Commissioner Martin Makary has proposed a dramatic expansion of the agency’s powers to speed up drug reviews, announcing on Tuesday a plan to evaluate new medicines that address U.S. “national interests,” like a health crisis, in just one to two months.

  • FDA to speed reviews for drugs supporting ‘national interests’

    1 week ago | biopharmadive.com | Jonathan Gardner

    Food and Drug Administration Commissioner Martin Makary has proposed a dramatic expansion of the agency’s powers to speed up drug reviews, announcing on Tuesday a plan to evaluate new medicines that address U.S. “national interests,” like a health crisis, in just one to two months.

  • Roche, waving off study failures, commits to Phase 3 trials for Parkinson’s drug

    1 week ago | biopharmadive.com | Jonathan Gardner

    Dive Brief:Roche will advance an experimental Parkinson’s disease drug with a mixed track record into late-stage development, announcing Monday that it is “encouraged by the efficacy signals” the medicine displayed in earlier testing despite missing its main objectives in two clinical trials.

  • Novo, searching for a spark, plans late-stage trials for amylin drug

    2 weeks ago | biopharmadive.com | Jonathan Gardner

    Dive Brief:Novo Nordisk is planning Phase 3 clinical trials for a obesity drug combination called amycretin, adding another emerging weight-loss medicine to the list of prospects it has in advanced testing. The Danish drugmaker said Thursday the trials could begin in early 2026, and will test both an injectable and an oral formulation.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers
3K
Tweets
9K
DMs Open
No
Jon Gardner
Jon Gardner @ByJonGardner
30 Oct 23

Coming out of hibernation (see me at BlueSky!) to look at the $SRPT stream and remind everybody ....

Jon Gardner
Jon Gardner @ByJonGardner

1/ "It's always good news for $SRPT!" is a phrase I began tweeting back in the days when $SRPT was in a neck-and-neck race with $BMRN to get the first exon-skipping agent on the market.

Jon Gardner
Jon Gardner @ByJonGardner
21 Nov 22

I love these M&A drawings. $TEVA https://t.co/ppVQSrBtRq

Jon Gardner
Jon Gardner @ByJonGardner
11 Nov 22

It would be an interesting end to the PARP story if it turned out that, like iniparib, none of the PARPs actually inhibited PARP. $AZN $GSK $CLVS $MRK